Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Campione E, Artosi F, Shumak RG, Giunta A, Argenziano G, Assorgi C, Balato A, Bernardini N, Brunasso AMG, Burlando M, Caldarola G, Campanati A, Carugno A, Castelli F, Conti A, Costanzo A, Cuccia A, Dapavo P, Dattola A, De Simone C, Di Lernia V, Dini V, Donini M, Errichetti E, Esposito M, Fargnoli MC, Foti A, Fiorella C, Gargiulo L, Gisondi P, Guarneri C, Legori A, Lembo S, Loconsole F, Malagoli P, Marzano AV, Mercuri SR, Megna M, Micali G, Mortato E, Musumeci ML, Narcisi A, Offidani AM, Orsini D, Paolino G, Pellacani G, Peris K, Potenza C, Prignano F, Quaglino P, Ribero S, Richetta AG, Romanelli M, Rossi A, Strippoli D, Trovato E, Venturini M, Bianchi L. Campione E, et al. Among authors: potenza c. Pharmaceuticals (Basel). 2024 Oct 16;17(10):1378. doi: 10.3390/ph17101378. Pharmaceuticals (Basel). 2024. PMID: 39459016 Free PMC article.
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study.
Dattola A, Balato A, Megna M, Gisondi P, Girolomoni G, De Simone C, Caldarola G, Cama E, Piaserico S, Fargnoli MC, Fidanza R, Parodi A, Burlando M, Offidani A, Diotallevi F, Potenza C, Conti A, Chiricozzi A, Campione E, Bianchi L. Dattola A, et al. Among authors: potenza c. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2839-2845. doi: 10.1111/jdv.16606. Epub 2020 Jun 26. J Eur Acad Dermatol Venereol. 2020. PMID: 32401377
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.
Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, Bardazzi F, Calzavara Pinton P, Campanati A, Cattaneo A, Dapavo P, De Simone C, Dini V, Fargnoli MC, Flori ML, Galluzzo M, Guarneri C, Lasagni C, Loconsole F, Lo Schiavo A, Malagoli P, Malara G, Mercuri SR, Musumeci ML, Naldi L, Papini M, Parodi A, Potenza C, Prignano F, Rongioletti F, Stingeni L, Tiberio R, Venturini M, Bianchi L, Costanzo A, Cusano F, Girolomoni G, Offidani AM, Peris K. Gisondi P, et al. Among authors: potenza c. Dermatol Ther (Heidelb). 2021 Feb;11(1):235-252. doi: 10.1007/s13555-020-00475-8. Epub 2021 Jan 11. Dermatol Ther (Heidelb). 2021. PMID: 33426634 Free PMC article.
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A, Costanzo A, Fargnoli MC, Malagoli P, Piaserico S, Amerio P, Argenziano G, Balato N, Bardazzi F, Bianchi L, Carrera CG, Conti A, Dapavo P, De Simone C, Loconsole F, Lo Schiavo A, Malara G, Musumeci ML, Parodi A, Peris K, Prignano F, Rongioletti F, Talamonti M, Potenza C. Chiricozzi A, et al. Among authors: potenza c. Eur J Dermatol. 2021 Feb 1;31(1):3-16. doi: 10.1684/ejd.2021.3965. Eur J Dermatol. 2021. PMID: 33648915 Review.
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Costanzo A, Russo F, Galluzzo M, Stingeni L, Scuderi R, Zichichi L, Papini M, Di Costanzo L, Conti A, Burlando M, Chiricozzi A, Gaiani FM, Mugheddu C, Musumeci ML, Gisondi P, Piaserico S, Dapavo P, Venturini M, Pagnanelli G, Amerio P, Potenza C, Peris K, Cantoresi F, Trevisini S, Loconsole F, Offidani A, Mercuri SR, Lora V, Prignano F, Bartezaghi M, Oliva G, Aloisi E, Orsenigo R. Costanzo A, et al. Among authors: potenza c. Acta Derm Venereol. 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816. Acta Derm Venereol. 2021. PMID: 33903916 Free PMC article. Clinical Trial.
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.
Campanati A, Atzori L, Potenza C, Damiani G, Bianchi L, Corazza M, Tiberio R, Prignano F, Argenziano G, Fargnoli MC, Stingeni L, Mazzotta A, De Pità O, Mazzatenta C, Feliciani C, Donini M, Offidani A, Peris K; LION study group. Campanati A, et al. Among authors: potenza c. Dermatol Ther. 2021 Sep;34(5):e15077. doi: 10.1111/dth.15077. Epub 2021 Aug 9. Dermatol Ther. 2021. PMID: 34333823 Free PMC article.
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Caldarola G, Galluzzo M, Bernardini N, Calabrese L, Grimaldi M, Moretta G, Pagnanelli G, Shumak RG, Talamonti M, Tofani L, Pallotta S, Peris K, Potenza C, De Simone C, Campione E. Caldarola G, et al. Among authors: potenza c. Dermatol Ther. 2022 Jun;35(6):e15488. doi: 10.1111/dth.15488. Epub 2022 Apr 11. Dermatol Ther. 2022. PMID: 35384168 Free PMC article.
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M, Talamonti M, Bernardini N, Chiricozzi A, De Simone C, Bonifati C, Bruni P, Diotallevi F, Esposito M, Graceffa D, Hansel K, Loconsole F, Moretta G, Mugheddu C, Papini M, Richetta A, Skroza N, Atzori L, Fargnoli MC, Persechino S, Offidani A, Stingeni L, Peris K, Potenza C, Bianchi L. Galluzzo M, et al. Among authors: potenza c. Expert Opin Biol Ther. 2022 Dec;22(12):1585-1592. doi: 10.1080/14712598.2022.2090835. Epub 2022 Jun 22. Expert Opin Biol Ther. 2022. PMID: 35708257
200 results